NASDAQ:CNST Constellation Pharmaceuticals (CNST) Stock Price, News & Analysis → Gold Set to EXPLODE! (From Gold Safe Exchange) (Ad) Free CNST Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$33.99▼$33.9950-Day Range$33.63▼$33.9952-Week Range$17.00▼$39.30VolumeN/AAverage Volume940,325 shsMarket Capitalization$1.63 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Constellation Pharmaceuticals alerts: Email Address Ad Chaikin AnalyticsA.I. is a Tidal Wave - Here’s What to BuyThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture.Get the name and ticker symbol for free - just click here. About Constellation Pharmaceuticals Stock (NASDAQ:CNST)Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Read More Ad Chaikin AnalyticsA.I. is a Tidal Wave - Here’s What to BuyThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture.Get the name and ticker symbol for free - just click here. CNST Stock News HeadlinesApril 20, 2023 | chron.comYour guide to Constellation Field, home of the Sugar Land Space CowboysMarch 8, 2023 | forbes.comConstellation SoftwareMay 11, 2024 | Chaikin Analytics (Ad)A.I. is a Tidal Wave - Here’s What to BuyThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture.January 15, 2023 | thestreet.comConstellation Brands Inc. NewsDecember 11, 2022 | cnet.comStarlink Explained: What You Need to Know About Elon Musk's Satellite Internet ServiceJanuary 19, 2022 | bizjournals.comFormer execs at bluebird, Constellation join VC firm Third RockSee More Headlines Receive CNST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Constellation Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2021Today5/11/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:CNST CUSIP21036U206 CIK29806 Webwww.constellationpharma.com Phone617-714-0555FaxN/AEmployees154Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-126,360,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-33.12% Return on Assets-29.92% Debt Debt-to-Equity RatioN/A Current Ratio15.39 Quick Ratio15.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.63 per share Price / Book3.94Miscellaneous Outstanding Shares47,915,000Free FloatN/AMarket Cap$1.63 billion OptionableNot Optionable Beta2.59 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Jigar RaythathaPres, CEO & DirectorMs. Emma Reeve (Age 60)Chief Financial Officer Comp: $562.98kDr. Patrick Trojer Ph.D. (Age 48)Sr. VP & Chief Scientific Officer Comp: $556.52kMs. Karen Higgins Valentine J.D. (Age 49)Sr. VP, Chief Legal Officer & Gen. Counsel Comp: $535.93kDr. Jeffrey Humphrey M.D. (Age 59)Chief Medical Officer Comp: $462.25kDr. Danny ReinbergCo-FounderDr. Yang Shi Ph.D.Co-FounderDr. David AllisCo-FounderMr. Mohan Bala Ph.D.Chief Operating OfficerMr. Ronald Aldridge (Age 67)Sr. Director of Investor Relations More ExecutivesKey CompetitorsAvadel PharmaceuticalsNASDAQ:AVDLKura OncologyNASDAQ:KURAZai LabNASDAQ:ZLABTaro Pharmaceutical IndustriesNYSE:TAROSupernus PharmaceuticalsNASDAQ:SUPNView All Competitors CNST Stock Analysis - Frequently Asked Questions How were Constellation Pharmaceuticals' earnings last quarter? Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) announced its quarterly earnings results on Sunday, May, 9th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.79) by $0.05. What is Jigar Raythatha's approval rating as Constellation Pharmaceuticals' CEO? 10 employees have rated Constellation Pharmaceuticals Chief Executive Officer Jigar Raythatha on Glassdoor.com. Jigar Raythatha has an approval rating of 100% among the company's employees. This puts Jigar Raythatha in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Constellation Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Constellation Pharmaceuticals investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Applied Materials (AMAT), Inovio Pharmaceuticals (INO), Intel (INTC), NVIDIA (NVDA), Pfizer (PFE), Sorrento Therapeutics (SRNE), Cisco Systems (CSCO) and AT&T (T). When did Constellation Pharmaceuticals IPO? Constellation Pharmaceuticals (CNST) raised $80 million in an initial public offering on Thursday, July 19th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager. This page (NASDAQ:CNST) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchCollapse of the Petrodollar Colonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Constellation Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.